Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer
-
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
-
IO Biotech to Present at 44th Annual Cowen Health Care Conference
-
IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial
-
IO Biotech Announces 2023 Third Quarter Results
-
IO Biotech Appoints Helen Collins, MD, to its Board of Directors
-
IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma
-
IO Biotech Announces Participation in Upcoming Investor Conferences
-
IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting